“The best case scenario in 2029 would be that we are, you know, on the cusp of approval in schizophrenia, that we are successful in bipolar, depression and moving to phase three and, you know, on the verge of reading out what hopefully will be positive data in in a phase two adjunctive MDD trial.”
→ Read the source episode
By end of 2029, LB Pharma has submitted or is preparing to submit NDA for schizophrenia indication; has positive phase three bipolar depression data; has positive phase two adjunctive MDD data.
Avalon will initiate Phase 3 trials for APL1 and APO2 following Phase 2 data readouts in 2027
Heather Turner predicts LB102 will demonstrate efficacy across multiple serious neuropsychiatric indications beyond schizophrenia.
Avalon will have Phase 2b data readout for APL1 (inhaled pirfenidone) in the second half of 2027
Avalon will have Phase 2 data readout for APO2 (inhaled nintedanib) in late 2027
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.